5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Agile Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was 16.50%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Agile Therapeutics's 5-Year ROIIC % or its related term are showing as below:
AGRX's 5-Year ROIIC % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.48
vs AGRX: 16.50
Agile Therapeutics 5-Year ROIIC % Historical Data
The historical data trend for Agile Therapeutics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Agile Therapeutics's 5-Year ROIIC %
For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agile Therapeutics's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Agile Therapeutics's 5-Year ROIIC % falls into.
Agile Therapeutics 5-Year ROIIC % Calculation
Agile Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -19.884 (Dec. 2023) - -18.080874 (Dec. 2018) )
/
( 3.629 (Dec. 2023) - 14.555 (Dec. 2018) )
=
-1.803126
/
-10.926
=
16.50%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Agile Therapeutics 5-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Agile Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your 